MedTrace Logo

Safety and Efficacy Study of Adjunctive Rosiglitazone in the Treatment of Uncomplicated Falciparum Malaria

NCT00149383 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2015-04-13

No results posted yet for this study

Summary

The purpose of this study is to examine the safety, tolerability, and efficacy of adjunctive rosiglitazone in the treatment of uncomplicated P.falciparum malaria.

Conditions

  • Falciparum Malaria

Interventions

DRUG

Rosiglitazone

DRUG

Placebo

Sponsors & Collaborators

  • McLaughlin-Rotman Center for Global Health, University of Toronto

    collaborator OTHER

  • Mahidol University

    lead OTHER

Principal Investigators

  • Kevin C Kain, MD, FRCPC · Faculty of Medicine, University of Toronto; McLaughlin-Rotman Center for Global Health, Toronto

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2005-11-30
Completion
2006-01-31

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00149383 on ClinicalTrials.gov